|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GPR37 |
Gene summary for GPR37 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GPR37 | Gene ID | 2861 |
| Gene name | G protein-coupled receptor 37 | |
| Gene Alias | EDNRBL | |
| Cytomap | 7q31.33 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | O15354 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2861 | GPR37 | HCC1_Meng | Human | Liver | HCC | 8.34e-10 | 6.17e-03 | 0.0246 |
| 2861 | GPR37 | HCC1 | Human | Liver | HCC | 1.14e-04 | 2.83e+00 | 0.5336 |
| 2861 | GPR37 | S014 | Human | Liver | HCC | 5.71e-41 | 1.34e+00 | 0.2254 |
| 2861 | GPR37 | S015 | Human | Liver | HCC | 1.87e-40 | 1.44e+00 | 0.2375 |
| 2861 | GPR37 | S016 | Human | Liver | HCC | 9.97e-47 | 1.58e+00 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000697922 | Liver | HCC | response to oxidative stress | 281/7958 | 446/18723 | 9.75e-19 | 1.24e-16 | 281 |
| GO:006219722 | Liver | HCC | cellular response to chemical stress | 216/7958 | 337/18723 | 6.86e-16 | 5.44e-14 | 216 |
| GO:003459922 | Liver | HCC | cellular response to oxidative stress | 183/7958 | 288/18723 | 3.65e-13 | 1.93e-11 | 183 |
| GO:000030222 | Liver | HCC | response to reactive oxygen species | 144/7958 | 222/18723 | 1.24e-11 | 5.09e-10 | 144 |
| GO:004254222 | Liver | HCC | response to hydrogen peroxide | 100/7958 | 146/18723 | 1.79e-10 | 6.15e-09 | 100 |
| GO:003461412 | Liver | HCC | cellular response to reactive oxygen species | 102/7958 | 155/18723 | 3.70e-09 | 9.89e-08 | 102 |
| GO:00703011 | Liver | HCC | cellular response to hydrogen peroxide | 66/7958 | 98/18723 | 5.74e-07 | 9.07e-06 | 66 |
| GO:19016172 | Liver | HCC | organic hydroxy compound biosynthetic process | 129/7958 | 237/18723 | 1.32e-04 | 1.08e-03 | 129 |
| GO:003647312 | Liver | HCC | cell death in response to oxidative stress | 55/7958 | 95/18723 | 1.76e-03 | 9.12e-03 | 55 |
| GO:190288212 | Liver | HCC | regulation of response to oxidative stress | 55/7958 | 98/18723 | 4.46e-03 | 1.93e-02 | 55 |
| GO:190040712 | Liver | HCC | regulation of cellular response to oxidative stress | 50/7958 | 89/18723 | 6.33e-03 | 2.58e-02 | 50 |
| GO:190320112 | Liver | HCC | regulation of oxidative stress-induced cell death | 42/7958 | 74/18723 | 9.32e-03 | 3.57e-02 | 42 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501222 | Liver | HCC | Parkinson disease | 198/4020 | 266/8465 | 9.40e-20 | 1.58e-17 | 8.76e-18 | 198 |
| hsa0502222 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
| hsa0501232 | Liver | HCC | Parkinson disease | 198/4020 | 266/8465 | 9.40e-20 | 1.58e-17 | 8.76e-18 | 198 |
| hsa0502232 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| PSAP | GPR37L1 | PSAP_GPR37L1 | PSAP | HNSCC | Precancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GPR37 | SNV | Missense_Mutation | c.1100N>C | p.Gln367Pro | p.Q367P | O15354 | protein_coding | tolerated(0.07) | probably_damaging(0.953) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| GPR37 | SNV | Missense_Mutation | rs538782485 | c.1397N>T | p.Ala466Val | p.A466V | O15354 | protein_coding | tolerated(0.09) | possibly_damaging(0.874) | TCGA-A2-A0T4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | femara | SD |
| GPR37 | SNV | Missense_Mutation | c.462G>T | p.Lys154Asn | p.K154N | O15354 | protein_coding | tolerated(0.07) | benign(0.051) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GPR37 | SNV | Missense_Mutation | novel | c.457G>A | p.Glu153Lys | p.E153K | O15354 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| GPR37 | SNV | Missense_Mutation | novel | c.203N>A | p.Arg68Gln | p.R68Q | O15354 | protein_coding | tolerated_low_confidence(0.09) | benign(0.062) | TCGA-EW-A1PC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| GPR37 | SNV | Missense_Mutation | novel | c.842C>T | p.Ala281Val | p.A281V | O15354 | protein_coding | deleterious(0.02) | possibly_damaging(0.89) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GPR37 | SNV | Missense_Mutation | c.1774N>A | p.Glu592Lys | p.E592K | O15354 | protein_coding | deleterious(0.03) | possibly_damaging(0.647) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| GPR37 | SNV | Missense_Mutation | c.744N>T | p.Lys248Asn | p.K248N | O15354 | protein_coding | tolerated(0.07) | benign(0.141) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| GPR37 | SNV | Missense_Mutation | novel | c.918N>T | p.Trp306Cys | p.W306C | O15354 | protein_coding | deleterious(0.03) | possibly_damaging(0.714) | TCGA-AA-3519-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| GPR37 | SNV | Missense_Mutation | c.856G>C | p.Val286Leu | p.V286L | O15354 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-AA-3692-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2861 | GPR37 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | agonist | 178102688 | ||
| 2861 | GPR37 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | agonist | 135652325 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |